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2589-5370/© 2018 Published by Elsevier Ltd. TIn the last three decades, several studies underlined the clinical and
CPAP treatment (3.3 h/night) [8]. Finally, the possibility that subgroupspathophysiological links between obstructive sleep apnea (OSA) and
cardiovascular risk [1]. Clinically, OSA patients are generally obese,
often affected by systemic hypertension, diabetes, and dyslipidemia,
and show a high prevalence of cardiovascular and cerebrovascular dis-
eases [2]. Studies aimed at dissecting the pathophysiology of cardiovas-
cular risk in OSA identified several intermediate mechanisms.
Intermittent hypoxia during sleep is considered the main pathogenetic
factor, and is associated with elevated sympathetic nervous activity,
nocturnal blood pressure surges at the end of apneas, endothelial cell
dysfunction and oxidative stress, inflammation and accelerated athero-
sclerosis [2]. In patients with type 2 diabetes, OSA is highly prevalent
and may worsen metabolic disturbances, not only through the meta-
bolic effects of hypoxia, but also by inducing sleep fragmentation
which also negatively affects glucose metabolism [3]. The results of a
longitudinal population study in over 150,000 subjects [4] support the
concept of a bidirectional relationship between OSA and diabetes [3].
Longitudinal observational studies in OSA patients showed in-
creased cardiovascular morbidity and mortality in untreated severe
OSA, and a protective effect of CPAP treatment [5]. However, random-
ized controlled studies (RCTs) on the effects of CPAP on cardiovascular
outcomes, such as the multicenter Sleep Apnea Cardiovascular End-
points (SAVE) study [6], failed to show any protective effect of CPAP
treatment on a composite cardiovascular endpoint in non-sleepy OSA
patients with known coronary or cerebrovascular disease followed for
3.7 years. A recent meta-analysis including only RCTs on this topic016/j.eclinm.2018.09.002.
artment of Internal Medicine and Medical
AOUP Paolo Giaccone University Hospital,
his is an open access article under the CC BY-NCreached similar conclusions but found a protective effect of CPAP use
for ≥4 h/night [7].
The results of the SAVE study were cautiously acknowledged by the
sleep community [8], as they cannot be extrapolated to symptomatic
patients with OSA and daytime sleepiness. For ethical reasons, lack of
daytime sleepiness was an inclusion criteria in the SAVE study, as in
other long-term RCTs, and may in part explain the low adherence to
of patients at particularly high cardiovascular risk might benefit from
CPAP treatment was not tested.
The study by Quan and coworkers [9] re-analyzed the data of the
SAVE study by using latent class analysis to assess whether:
a) subgroups of patients may show high risk for the composite cardio-
vascular outcome, and b) adequate CPAP use might be protective in
such subgroups. Occurrence of diabetes in OSA patients with CAD or ce-
rebrovascular disease increased the risk for the composite outcome,
while adequate CPAP treatment, i.e. at least 4 h/night, decreased cardio-
vascular risk in diabetic patients with OSA, with the strongest effect in
patients with cerebrovascular disease.
These results suggest that CPAP treatmentmight be protective in di-
abetic OSA patients, and efforts should bemade to improve CPAP adher-
ence in these patients. According to recent studies, the detrimental
effects of OSAmight be especially relevant in patients withmultiple co-
morbidities, including diabetes [10]. In such patients, CPAP treatment
may prevent mortality [11] or cardiovascular events [12].
While the study by Quan and coworkers carries a more optimistic
view about the effects of CPAP treatment compared to the previous re-
sults of SAVE, some points deserve comment. First, the results should be
replicated in other cohorts, also in consideration of the peculiar distribu-
tion of CAD-cerebrovascular disease according to race and gender in the
SAVE cohort. Second, the mechanism of the protective effect of CPAP
should be clarified. To date, evidence that CPAP treatment improves gly-
cemic control in diabetic OSA patients is lacking [13]. On the other hand,
compared to usual metabolic markers, assessment of end-organ dam-
age could provide a better estimate of the impact of OSA and its treat-
ment in diabetic patients [14,15]. Third, phenotypic characterization of
OSA patients may identify other clusters, allowing refinement of the
therapeutic approach. In addition to new RCTs on the effects of OSA
treatment in patients with well-defined risk profiles, analysis of “big
data” in large observational cohorts of OSA patients may help to over-
come the limitations of RCTs, as discussed in a recent pro-con debate
[8,16].-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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OSA patients [17], but the development of personalized medicine for
OSA will require model validation in different cohorts, together with
new analytical approaches. The results of the new analysis of the SAVE
data suggest the opportunity to treat OSA in diabetics, but the big ques-
tion on the effects of CPAP on cardiovascular outcomes remains open at
the moment, and awaits further study.
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